Resources to Enhance the Adjustment of Children (REACH) (REACH)
Oppositional Defiant Disorder, Conduct Disorder, Attention Deficit Hyperactivity Disorder
About this trial
This is an interventional treatment trial for Oppositional Defiant Disorder focused on measuring Cognitive Behavioral Therapy, Multimodal Treatment, Physiological Parameters, Hormone Concentration in pubertal development, Treatment as usual comparison
Eligibility Criteria
All participants were enrolled in the initial "parent" study and criteria for initial enrollment included:
Inclusion Criteria:
- males or females with an age of 6-11 years,
- a DSM-IV diagnosis of CD or ODD,
- residence with at least one parent/guardian;
- intellectual level no less than two SD's below age norms; and
- parent consent for participation.
Exclusion Criteria:
- concurrent individual or family participation in a treatment program directed towards the child's disruptive disorders,
- current psychosis, bipolar disorder, or MDD marked by significant vegetative signs,
- suicidality with a plan or homicidality; or
- substance abuse or an eating disorder.
Sites / Locations
- Cincinnati Children's Hospital Medical Center
- Bellefield Towers - Western Psychiatric Institute and Clinic
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Active Comparator
Other
Acute Treatment Protocol Booster
Acute Treatment Protocol No-Booster
Treatment As Usual
No Intervention Healthy Comparison
Child participants in this arm were initial participants enrolled in the parent study and randomized to receive the specialty treatment from study clinicians in either the clinic or community setting. In this continuation study, the participants were enrolled at the 36 month assessment and randomized to participate in the booster dose of treatment. The treatment provided in this arm includes specific booster treatment based on the 8 modules of the initial treatment study. Saliva samples were also collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
Child participants in this arm were initial participants enrolled in the parent study and randomized to receive the specialty treatment from study clinicians in either the clinic or community setting. In this continuation study, the participants were enrolled at the 36 month assessment and randomized to participate in assessments only thus not receiving any additional booster treatment. Saliva samples were collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
Child participants in this arm were initial participants enrolled in the parent study in the clinically referred Treatment As Usual comparison group. These participants were initially enrolled in treatment services with identified providers and received treatment services as provided in that community agency. In this continuation study, the participants were enrolled at the 36 month assessment and participated in the ongoing follow-up assessments only. Saliva samples were collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
The Healthy Control subjects enrolled initially in the parent study are incorporated in a related project designed to evaluate the role of biological measures in differentiating antisocial and normal children. All Healthy Control participants were initially matched to cases in the clinical sample (both the acute treatment and the clinically referred Treatment as Usual).